IP Library Granted Patent US 11,324,774
Granted Patent B2
US 11,324,774 · App. 16/237,885 · Granted May 10, 2022

Compositions of oral alkaline salts and metabolic acid inducers and uses thereof

Inventors: Paul O'Connor (Martinez, GA); Ryan Harris (Augusta, GA)
Assignee: Augusta University Research Institute, Inc.
A61K33/00A61K9/0056A61K9/08A61K31/198A61P3/04A61P3/10A61P9/10A61P9/12A61P29/00A61K9/0095
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,324,774
App. No.
16/237,885
Granted
May 10, 2022
Kind
B2
Abstract

Compositions of alkaline salts and metabolic acid inducers and methods of use thereof are provided. The disclosed compositions may be used for stimulating vagal nerve efferent pathways, treating or preventing an inflammatory response or an autoimmune disorder, inhibiting or reducing one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood, promoting polarization of macrophages from a pro-inflammatory M1 state to an anti-inflammatory M2 state, and treating or preventing cardiovascular disease or metabolic disorders.

Claims (19)

1. A method for treating an inflammatory condition associated with vagal nerve efferent pathways in a subject in need thereof, comprising:

orally administering to the subject a solution consisting of equimolar amounts of sodium bicarbonate in an amount of about 0.01 M to about 0.5 M and ammonium (NH 4 + ) in water in an amount effective to increase the pH of the stomach to at least 6-9 to activate vagal nerve efferent pathways to reduce or inhibit the inflammation,

wherein the solution of the sodium bicarbonate and the ammonium in equimolar amounts provides selective stomach alkalization without systemic alkalization.

2. The method of claim 1 , wherein the solution of sodium bicarbonate and the ammonium (NH 4 + ) is in effective amounts to inhibit or reduce one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils in the blood of the subject.

3. The method of claim 1 , wherein the solution of sodium bicarbonate and the ammonium (NH 4 + ) is in effective amounts to inhibit or reduce one or more pro-inflammatory cytokines selected from the group consisting of IL1α, IL1β, IL6, and TNFα.

4. The method of claim 1 , wherein the inflammatory condition is selected from the group consisting of chronic kidney disease, rheumatoid arthritis, inflammatory bowel disease, and Crohn's disease.

5. A method of stimulating vagal nerve efferent pathways in a subject in need thereof, comprising:

orally administering to the subject a solution consisting of equimolar amounts of sodium bicarbonate in an amount of about 0.01 M to about 0.5 M and ammonium (NH 4 + ) in water in an amount effective to increase the pH of the stomach to at least 6-9 to stimulate vagal nerve efferent pathways,

wherein the solution of the sodium bicarbonate and the ammonium in equimolar amounts provides selective stomach alkalization without systemic alkalization.

6. The method of claim 5 , wherein the solution of the sodium bicarbonate and the ammonium is in effective amounts to alkalinize the pH of the stomach of the subject.

7. A solution,

consisting of equimolar amounts of sodium bicarbonate in an amount of about 0.01 M to about 0.5 M and ammonium (NH 4 + ) in water in an amount effective to increase the pH of the stomach to at least 6-9,

wherein the solution of the sodium bicarbonate and the ammonium in equimolar amounts provides selective stomach alkalization without systemic alkalization.

8. The solution of claim 7 , wherein the solution is formulated for oral administration.

9. The solution of claim 7 , wherein the solution is formulated as an extended release formulation.

10. The solution of claim 7 , wherein the solution of sodium bicarbonate and the ammonium (NH 4 + ) is in effective amounts to inhibit or reduce one or more inflammatory M1 macrophages and/or one or more inflammatory neutrophils and thereby inhibit or reduce inflammation in a subject.

11. A method for treating or preventing a cardiovascular disease or a metabolic disorder, comprising:

administering to a subject in need thereof an effective amount of the solution of claim 7 .

12. The method of claim 11 , wherein the cardiovascular disease or metabolic disorder is selected from the group consisting of atherosclerosis, hypertension, obesity, and type 2 diabetes.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2019
From: AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 049685/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: O'CONNOR, PAUL; HARRIS, RYAN
To: AUGUSTA UNIVERSITY
Reel/Frame 049675/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 5, 2019
From: AUGUSTA UNIVERSITY
To: AUGUSTA UNIVERSITY; AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Reel/Frame 049675/0658 →
CONFIRMATORY LICENSE Recorded Jan 22, 2019
From: AUGUSTA UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 048103/0876 →
Continuity (2)
Provisional Application 62613949 · Jan 5, 2018
Related Publication 20190231813A1 · Aug 1, 2019